Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2010

View Archived Issues

Pfizer reports on discovery and evaluation of PF-610355 for asthma/COPD

Alipogene tiparvovec shows safety and efficacy in subjects with LPL deficiency / News in Context

B7-H4 gene therapy combined with abatacept enhances experimental islet graft survival

PF-4457845 development and early clinical data reported at recent congresses

New GHRH receptor antagonists disclosed by sanofi-aventis

Faxeladol shows comparable safety and efficacy to tramadol in patients with painful polyneuropathy

E.U. approves Brinavess for rapid conversion of recent-onset AF

FDA updates Tygacil label to include increased mortality risk

FDA approves Omnitrope for idiopathic short stature

Biousian Biotechnology describes new delta-type opioid receptor agonists

PecFent receives European marketing authorization for breakthrough cancer pain

Halozyme begins phase II trials of PH-20 in type 1 and type 2 diabetes

New alpha 2B and 2C adrenoceptor agonists claimed by Allergan

NIH grants funding to Bionovo for obesity and metabolic syndrome study

LG Life Sciences discloses new xanthine oxidase inhibitors

MorphoSys and Absynth partner for MRSA treatments

Organon and Pharmacopeia claim new TRPV1 ligands

Eisai initiates phase I study of BAN-2401 in AD

Orexigen and Takeda to co-commercialize Contrave in North America

E.C. approves Seroquel XR as add-on treatment for major depressive disorder

Results reported from study of Cerus' INTERCEPT Blood System

iBio, Fraunhofer and GE Healthcare to partner for iBioLaunch platform

NIH awards Celsion grant to develop new oncology treatments

Ipsen gains rights to fipamezole outside of North America and Japan

MSD's Sycrest approved in Europe for biopolar disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...